Drug Profile


Alternative Names: AN 113111; GE 145

Latest Information Update: 25 May 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GE Healthcare
  • Developer Daiichi Sankyo Company; GE Healthcare
  • Class Amides; Aza compounds; Contrast media; Diagnostic agents; Imaging agents; Iodobenzenes; Small molecules
  • Mechanism of Action Tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Vascular disorders

Most Recent Events

  • 01 Dec 2012 GE Healthcare completes a phase II trial in Vascular disorders (diagnosis, in the elderly) in USA (NCT01252810)
  • 01 Aug 2012 GE Healthcare completes a phase I/II trial in Vascular disorders (healthy volunteers) in USA (NCT01672996)
  • 07 Jul 2012 GE Healthcare initiates enrolment in a phase I/II trial in Diagnostic imaging (in healthy volunteers) in USA (NCT01672996)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top